Guangzhou Kingmed Diagnostics Group Co., Ltd. is a leading independent clinical laboratory services provider in China, founded in 1994 and headquartered in Guangzhou. The company offers comprehensive medical diagnostic services including clinical laboratory testing, pathology, molecular diagnostics, clinical biochemistry, and gene-based testing; it operates more than 200 laboratories and 50 centralized labs across China, covering over 90% of the population with over 4000 test items available. Additional services include clinical research, health management, cold chain logistics, forensic testing, and scientific research services, enhanced by investments in artificial intelligence and big data technologies. Kingmed serves over 23,000 medical institutions and conducts over 70 million tests annually, focusing on high-value tests such as genetic screening and tumor marker detection. Recent significant developments include strategic partnerships to expand Alzheimer's disease diagnostic testing access, collaborations to introduce advanced genomic oncology technologies such as comprehensive genomic tissue panels for cancer patients, and ongoing investments to improve cold chain logistics capabilities. The company has also focused on integrating digital transformation initiatives with partners like Huawei Cloud to enhance AI-assisted diagnostic screening processes. Guangzhou Kingmed Diagnostics continues to strengthen its position through innovation, technology adoption, and expansion within China's vast diagnostic market and collaborates with global organizations to advance its medical testing solutions. Its broad geographic footprint spans mainland China and Hong Kong, targeting hospitals, research institutions, biotechnology firms, and other healthcare providers.